B.S., 2011, University of Maryland
Ilana is interested in understanding the cellular changes that occur downstream of mTORC1 in cancers treated with mTOR inhibitors. She is focused on defining targets that contribute to drug resistance when activated and developing dual combination approaches for targeting cancers with activated mTOR signaling.
Kelsey I, Manning BD. mTORC1 status dictates tumor response to targeted therapeutics. Sci Signal. 2013. 6(294):pe31. PMID: 24065143